Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adu…

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...

Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray, the First and Only FDA-Approve…

CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional ...
Seeking Alpha

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Milestone Pharmaceuticals Inc. receives a Strong Buy rating, driven by Cardamyst's FDA approval and imminent commercial launch for PSVT. MIST's Cardamyst demonstrated rapid efficacy, favorable safety, ...

Milestone’s PSVT nasal spray MAA accepted by EMA

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.
Investing

European regulators accept etripamil nasal spray application for PSVT

MONTREAL/CHARLOTTE - Milestone Pharmaceuticals Inc. (NASDAQ:MIST) announced Tuesday that the European Medicines Agency (EMA) has accepted its Marketing Authorization Application for etripamil nasal ...
Business Insider

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan.
PharmiWeb

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) ...
Morningstar

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the ...